Figure 2.

Summary of antiplatelet and anticoagulant therapies in individuals with diabetes and vascular disease. ACS: acute coronary syndrome; AF: atrial fibrillation; CAD: coronary artery disease; CVD: cerebrovascular disease; DAPT: dual antiplatelet therapy; NOAC: non-vitamin K antagonist oral anticoagulants; PAD: peripheral artery disease; SR: sinus rhythm. ^aDiabetes mellitus individuals with ≥1 organ damage or ≥3 major risk factors, or any risk factor and ≥10-year disease duration without organ damage. ^bActive bleeding or comorbidities with high bleeding risk. ^cHistory of intracerebral haemorrhage or ischaemic stroke, history of other intracranial pathology, recent gastrointestinal bleeding or anaemia due to possible gastrointestinal blood loss, other gastrointestinal pathology associated with increased bleeding risk, liver failure, bleeding diathesis or coagulopathy, extreme old age or frailty, or renal failure requiring dialysis or with estimated glomerular filtration rate <15 mL/min/1.73 m². ^dDiffuse multivessel CAD with at least one of the following: diabetes mellitus requiring medication, recurrent myocardial infarction, PAD, or chronic kidney disease with estimated glomerular filtration rate 15–59 mL/min/1.73 m².